Lonza Group (OTCMKTS:LZAGY) Upgraded at Zacks Research

Zacks Research upgraded shares of Lonza Group (OTCMKTS:LZAGY) from a strong sell rating to a hold rating in a research report sent to investors on Wednesday morning,Zacks.com reports.

Separately, Royal Bank Of Canada upgraded Lonza Group from a “hold” rating to a “moderate buy” rating in a report on Wednesday, February 11th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Lonza Group Stock Performance

Shares of LZAGY opened at $65.09 on Wednesday. Lonza Group has a 12-month low of $58.53 and a 12-month high of $73.85. The business has a 50-day simple moving average of $65.01 and a two-hundred day simple moving average of $67.04. The company has a quick ratio of 1.77, a current ratio of 2.24 and a debt-to-equity ratio of 0.42.

Lonza Group Company Profile

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.